Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | G6PD | P11413 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | CASP6 | P55212 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2179706 | 0.75 | ALDH1A1 (0.35) | ALDH1A1CASP7TDP1 | |
| SCHEMBL28883304 | 0.72 | CASP6 (0.40) | ALDH1A1MEN1POLBMAPTTHRB | |
| SCHEMBL3716519 | 0.70 | G6PD (0.55) | CA12CA1CA9ALDH1A1MEN1 | |
| SCHEMBL1834310 | 0.67 | CA12 (0.41) | CA12CA1CA9ALDH1A1MEN1 | |
| SCHEMBL20837977 | 0.65 | CA12 (0.42) | CA12CA1CA9ALDH1A1POLB | |
| SCHEMBL1832044 | 0.64 | ALB (0.43) | CA12CA1CA9ALDH1A1KMT2A | |
| SCHEMBL16875692 | 0.64 | CA12 (0.38) | CA12CA1CA9ALDH1A1MEN1 | |
| SCHEMBL690406 | 0.63 | CASP7 (0.58) | ALDH1A1MEN1POLBMAPTTHRB | |
| SCHEMBL29792992 | 0.63 | CASP7 (0.58) | ALDH1A1MEN1POLBMAPTTHRB | |
| SCHEMBL2898289 | 0.63 | CA12 (0.35) | CA12CA1CA9ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012149412-A2 | ANTI-ENDOGLIN (CD105) ANTIBODIES, IMMUNOCONJUGATES, AND USES THEREOF | IMMUNOGEN INC. (US) | 2012-11-01 | — | — | WO | claimed |
| WO-2012019024-A2 | HER3-BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF | IMMUNOGEN, INC. (US) | 2012-02-09 | — | — | WO | claimed |
| EP-1813614-B1 | Cytotoxic agents comprising new tomaymycin derivatives | SANOFI SA (FR) | 2011-10-05 | — | — | EP | claimed |
| EP-4731673-A1 | NECTIN-4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | Eli Lilly and Company (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20250000991-A1 | NECTIN-4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | LOXO ONCOLOGY, INC. | 2025-01-02 | — | — | US | disclosed |
| WO-2024263630-A1 | NECTIN-4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | ELI LILLY AND COMPANY (US) | 2024-12-26 | — | — | WO | disclosed |
| EP-4346906-A1 | ANTHRACYCLINE ANTIBODY CONJUGATES | Seagen Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| WO-2024030577-A1 | IMMUNOSTIMULATORY ANTI-PD-L1-DRUG CONJUGATES | SEAGEN INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| EP-4314043-A1 | CYSTEINE ENGINEERED ANTIBODY CONSTRUCTS, CONJUGATES AND METHODS OF USE | Zymeworks BC Inc. (CA) | 2024-02-07 | — | — | EP | disclosed |
| EP-4304660-A1 | METHODS FOR INCREASING EFFICACY OF IMMUNOCONJUGATES TARGETING ADAM9 FOR THE TREATMENT OF CANCER | ImmunoGen, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-4277904-A1 | IMMUNOMODULATORY ANTIBODY-DRUG CONJUGATES | Seagen Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| EP-1981889-A1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | Sanofi-Aventis (FR) | 2008-10-22 | — | — | EP | disclosed |
| US-20080220448-A1 | ANTIGENIC PROTEIN CONJUGATES AND PROCESS FOR PREPARING SAME | ABBOTT LABORATORIES | 2008-09-11 | — | — | US | disclosed |
| WO-2008027944-A2 | ANTIGENIC PROTEIN CONJUGATES AND PROCESS FOR PREPARING SAME | ABBOTT LABORATORIES (US) | 2008-03-06 | — | — | WO | disclosed |
| US-20080021005-A1 | Pegylated Ion Channel Modulating Compounds | CARDIOME PHARMA CORP. (CA) | 2008-01-24 | — | — | US | disclosed |
| WO-2007085930-A1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2007-08-02 | — | — | WO | disclosed |
| EP-1729814-A2 | PEGYLATED ION CHANNEL MODULATING COMPOUNDS | Cardiome Pharma Corp. (CA) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005097203-A2 | SERUM PROTEIN CONJUGATES OF ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005094897-A2 | PEGYLATED ION CHANNEL MODULATING COMPOUNDS | CARDIOME PHARMA CORP. (CA) | 2005-10-13 | — | — | WO | disclosed |
| US-6159686-A | Up-converting reporters for biological and other assays | SRI INTERNATIONAL (US) | 2000-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021005-A1 | Pegylated Ion Channel Modulating Compounds | KCNN3, KCNN2, KCNN1 | CA12 2868/4885CA1 1389/4885CA9 3747/4885 |
| US-20080220448-A1 | ANTIGENIC PROTEIN CONJUGATES AND PROCESS FOR PREPARING SAME | PTMS, SPR, DNPEP | CA12 416/4885CA1 1216/4885CA9 1088/4885 |
| US-20250000991-A1 | NECTIN-4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | NECTIN4, EPCAM, FUT4 | CA12 437/4885CA1 2208/4885CA9 1671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.